KR20170020514A - 중증 고중성지방혈증의 치료 - Google Patents

중증 고중성지방혈증의 치료 Download PDF

Info

Publication number
KR20170020514A
KR20170020514A KR1020177002016A KR20177002016A KR20170020514A KR 20170020514 A KR20170020514 A KR 20170020514A KR 1020177002016 A KR1020177002016 A KR 1020177002016A KR 20177002016 A KR20177002016 A KR 20177002016A KR 20170020514 A KR20170020514 A KR 20170020514A
Authority
KR
South Korea
Prior art keywords
mbx
composition
compound
niacin
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177002016A
Other languages
English (en)
Korean (ko)
Inventor
폴 부드
윤정 최
로버트 엘 마틴
찰스 에이 맥위어터
Original Assignee
사이머베이 쎄라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이머베이 쎄라퓨틱스, 인코퍼레이티드 filed Critical 사이머베이 쎄라퓨틱스, 인코퍼레이티드
Publication of KR20170020514A publication Critical patent/KR20170020514A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177002016A 2014-06-26 2015-06-25 중증 고중성지방혈증의 치료 Withdrawn KR20170020514A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
US62/017,444 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
KR20170020514A true KR20170020514A (ko) 2017-02-22

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002016A Withdrawn KR20170020514A (ko) 2014-06-26 2015-06-25 중증 고중성지방혈증의 치료

Country Status (16)

Country Link
US (1) US20150374649A1 (enExample)
EP (1) EP3160458A1 (enExample)
JP (1) JP2017519028A (enExample)
KR (1) KR20170020514A (enExample)
CN (1) CN106470675A (enExample)
AU (1) AU2015279905A1 (enExample)
BR (1) BR112016028918A2 (enExample)
CA (1) CA2951280A1 (enExample)
CL (1) CL2016003290A1 (enExample)
EA (1) EA201790091A1 (enExample)
HK (1) HK1231380A1 (enExample)
IL (1) IL249757A0 (enExample)
MX (1) MX2016017081A (enExample)
PH (1) PH12016502415A1 (enExample)
SG (1) SG11201610243YA (enExample)
WO (1) WO2015200580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3119384T1 (sl) 2014-03-20 2018-12-31 Cymabay Therapeutics, Inc. Zdravljenje intrahepatičnih holestatičnih bolezni
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HRP20192299T1 (hr) 2014-04-11 2020-03-06 Cymabay Therapeutics, Inc. Liječenje nafld i nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE542793T1 (de) 2003-09-19 2012-02-15 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
MA34097B1 (fr) * 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1

Also Published As

Publication number Publication date
EP3160458A1 (en) 2017-05-03
WO2015200580A1 (en) 2015-12-30
BR112016028918A2 (pt) 2017-08-22
MX2016017081A (es) 2017-05-01
CA2951280A1 (en) 2015-12-30
SG11201610243YA (en) 2017-01-27
AU2015279905A1 (en) 2017-02-02
PH12016502415A1 (en) 2017-02-27
EA201790091A1 (ru) 2017-07-31
US20150374649A1 (en) 2015-12-31
CL2016003290A1 (es) 2017-09-08
IL249757A0 (en) 2017-02-28
CN106470675A (zh) 2017-03-01
JP2017519028A (ja) 2017-07-13
HK1231380A1 (zh) 2017-12-22

Similar Documents

Publication Publication Date Title
RU2505292C2 (ru) Способы лечения гипертриглицеридемии
CA2944139C (en) Treatment of nafld and nash
KR20170020514A (ko) 중증 고중성지방혈증의 치료
JP5809115B2 (ja) 心血管イベント予防用製剤
JP5134916B2 (ja) 心血管イベント発症予防用組成物
EA011637B1 (ru) Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт
US20090182022A1 (en) Treatment of Fatty Liver
US20190183839A1 (en) Methods of treating pediatric metabolic syndrome
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
WO2014050692A1 (ja) 糖尿病新規発症低減用組成物
WO2007142118A1 (ja) 多重リスク患者の心血管イベント発症予防用組成物
CN102625847A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
BRPI0707670A2 (pt) composiÇço farmacÊutica, e, uso de um composto meglitinida
JP2010229099A (ja) 脂質異常症の改善または治療薬
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
JP4751257B2 (ja) 心血管イベント発症予防用組成物
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000